CELLULAR OXIDATIVE MODIFICATION OF LOW-DENSITY-LIPOPROTEIN DOES NOT REQUIRE LIPOXYGENASES

被引:98
作者
SPARROW, CP
OLSZEWSKI, J
机构
[1] Merck Sharp/Dohme Res. Lab., Atherosclerosis Research Dept., Rahway, NJ 07065
关键词
ATHEROSCLEROSIS; MACROPHAGE; ENDOTHELIAL CELL; CHOLESTEROL;
D O I
10.1073/pnas.89.1.128
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The oxidative modification of low density lipoprotein (LDL) may play an important role in the pathogenesis of atherosclerosis. LDL can be oxidatively modified in vitro by endothelial cells, mouse peritoneal macrophages, or copper ions. Studies using lipoxygenase inhibitors have suggested that lipoxygenase(s) is required for the cellular modification of LDL [Rankin, S. M., Parthasarathy, S. & Steinberg, D. (1991) J. Lipid Res. 32, 449-456]. We have reexamined the effect of lipoxygenase inhibitors on cellular modification and found that (i) inhibitors specific for 5-lipoxygenase do not block LDL modification; (ii) inhibitors that block lipoxygenase by donating one electron to the enzyme (reductive inactivation) prevent LDL modification by cells and also modification mediated by copper ions, implying that they act as general antioxidants; (iii) the lipoxygenase inhibitor 5,8,11,14-eicosatetraynoic acid blocks 15-lipoxygenase activity in intact macrophages at concentrations 100 times less than those required to block LDL modification by macrophages; and (iv) 5,8,11,14-eicosatetraynoic acid is cytotoxic at concentrations about twice those required to prevent modification. Furthermore, macrophages and the RECB4 line of endothelial cells modify LDL with similar efficiencies despite dramatic differences in 15-lipoxygenase activity. Thus we conclude that neither 5-lipoxygenase nor 15-lipoxygenase is required for modification of LDL by cultured cells.
引用
收藏
页码:128 / 131
页数:4
相关论文
共 40 条
[1]   (METHOXYALKYL)THIAZOLES - A NEW SERIES OF POTENT, SELECTIVE, AND ORALLY ACTIVE 5-LIPOXYGENASE INHIBITORS DISPLAYING HIGH ENANTIOSELECTIVITY [J].
BIRD, TGC ;
BRUNEAU, P ;
CRAWLEY, GC ;
EDWARDS, MP ;
FOSTER, SJ ;
GIRODEAU, JM ;
KINGSTON, JF ;
MCMILLAN, RM .
JOURNAL OF MEDICINAL CHEMISTRY, 1991, 34 (07) :2176-2186
[2]  
BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
[3]   BIOCHEMICAL AND BIOLOGICAL-ACTIVITIES OF 2,3-DIHYDRO-6-[3-(2-HYDROXYMETHYL)PHENYL-2-PROPENYL]-5-BENZOFURANOL (L-651,896), A NOVEL TOPICAL ANTIINFLAMMATORY AGENT [J].
BONNEY, RJ ;
DAVIES, P ;
DOUGHERTY, H ;
EGAN, RW ;
GALE, PH ;
CHANG, M ;
HAMMOND, M ;
JENSEN, N ;
MACDONALD, J ;
THOMPSON, K ;
ZAMBIAS, R ;
OPAS, EE ;
MEURER, R ;
PACHOLOK, S ;
HUMES, JL .
BIOCHEMICAL PHARMACOLOGY, 1987, 36 (22) :3885-3891
[4]  
BRYANT RW, 1982, J BIOL CHEM, V257, P6050
[5]  
BUCHANAN MR, 1985, J BIOL CHEM, V260, P6056
[6]   HORMONE AND NEUROTRANSMITER RECEPTORS IN AN ESTABLISHED VASCULAR ENDOTHELIAL CELL LINE [J].
BUONASSISI, V ;
VENTER, JC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1976, 73 (05) :1612-1616
[7]  
CARTER GW, 1991, J PHARMACOL EXP THER, V256, P929
[8]  
CATHCART MK, 1989, J IMMUNOL, V142, P1963
[9]   REQUIREMENT OF A 5-LIPOXYGENASE-ACTIVATING PROTEIN FOR LEUKOTRIENE SYNTHESIS [J].
DIXON, RAF ;
DIEHL, RE ;
OPAS, E ;
RANDS, E ;
VICKERS, PJ ;
EVANS, JF ;
GILLARD, JW ;
MILLER, DK .
NATURE, 1990, 343 (6255) :282-284
[10]   ENZYME INHIBITION BY ACETYLENIC COMPOUNDS [J].
DOWNING, DT ;
AHERN, DG ;
BACHTA, M .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1970, 40 (01) :218-&